Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trial.

Fiche publication

Date publication

février 2018

Journal

Journal of hepatology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr JOUVE Jean-Louis , Pr LEPAGE Côme , Dr MINELLO Anne , Pr LOFFROY Romaric , Pr SCHMITT Antonin , Dr WENDREMAIRE Maeva

Tous les auteurs :
Guiu B, Jouve JL, Schmitt A, Minello A, Bonnetain F, Cassinotto C, Piron L, Cercueil JP, Loffroy R, Latournerie M, Wendremaire M, Lepage C, Boulin M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29427728

Résumé

Idarubicin shows high cytotoxicity against hepatocellular carcinoma (HCC) cells, a high hepatic extraction ratio, and high lipophilicity leading to stable emulsions with lipiodol. A dose-escalation phase I trial of idarubicin_lipiodol (without embolisation) was conducted in patients with cirrhotic HCC to estimate the maximum-tolerated dose (MTD) and to assess the safety, efficacy, and pharmacokinetics of the drug, and the health-related quality of life achieved by patients.